Butylphthalide
Trials 26 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02149875 | Jan → May 2010 | cerebral artery occlusion | Shanghai 6th People's Hospital | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07518810 | Apr 2026 → Apr 2027 expected | multiple system atrophy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT02993367 | Jan 2017 → Jan 2019 | cognitive impairment with or without cerebellar ataxia | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07369999 | Feb 2026 → Mar 2029 expected | stroke disorder | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07252544 | Dec 2025 → Aug 2027 expected | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07230587 | Dec 2025 → Sep 2027 expected | ischemic stroke | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06704685 | Dec 2024 → Oct 2025 overdue | ST-elevation myocardial infarction | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03804229 | Oct 2019 → Oct 2024 overdue | vascular dementia | Capital Medical University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03539445 | Jul 2018 → May 2022 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01405248 | Jul 2011 → Jan 2014 | coronary restenosis | Jinling Hospital, China | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT07528456 | Apr 2026 → Apr 2027 expected | ischemic stroke | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07193277 | Sep 2025 → Dec 2027 expected | cognitive impairment with or without cerebellar ataxia, focal epilepsy | First Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06508671 | Jul 2024 → Dec 2025 overdue | chemotherapy-induced toxicity | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05068349 | May 2022 → Sep 2025 | brain ischemia, cerebral infarction | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06572085 | Jan 2022 → Dec 2027 expected | cardiac arrest | Tang Ziren | Recruiting | No outcome recorded |
| Phase 4 | NCT06353334 | Sep 2021 → Dec 2026 expected | cardiac arrest | Tang Ziren | Recruiting | No outcome recorded |
| Phase 4 | NCT04091412 | May 2019 → Jan 2020 | cerebral infarction, vascular occlusion disorder | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03413202 | Feb 2018 → Mar 2022 | ischemic stroke | Yi Yang | Completed | No outcome recorded |
| Phase 4 | NCT02594995 | Jul 2015 → Sep 2016 | anterior cerebral artery infarction, cerebral artery occlusion | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT00724724 | Aug 2008 → Jun 2011 | transient ischemic attack | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06968429 | May 2025 → Dec 2027 expected | migraine disorder | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06331494 | Mar 2024 → May 2026 overdue | cerebral atherosclerosis, ischemic stroke | First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT04664933 | Dec 2020 → May 2026 overdue | ischemic stroke, thrombotic disease | Huisheng Chen | Recruiting | No outcome recorded |
| — | NCT04664946 | Dec 2020 → May 2026 overdue | ischemic stroke | Huisheng Chen | Recruiting | No outcome recorded |
| — | NCT04078204 | Apr 2018 → Feb 2022 | cerebrovascular disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT03906123 | Nov 2017 → Dec 2019 | vascular dementia | Tianjin Medical University General Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04205578 Comparator | Jan 2020 → Dec 2022 | Moyamoya disease, cerebral infarction, transient ischemic attack | yuanli Zhao | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | butylphthalide | “Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising...” NCT07369999 ↗18“oral butylphthalide soft capsules for the prophylactic treatment of migraine in adults” NCT06968429 ↗ “Take 200 mg butylphthalide soft capsules (NBP) orally three times a day for 24 weeks” NCT06508671 ↗ |
| Known as | 3-n-butylphthalide | “Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min” NCT04664933 ↗2“Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.” NCT04664946 ↗ |
| Known as | Butylphthalide and Sodium Chloride Injection | “For patients in the butylphthalide group, Butylphthalide and Sodium Chloride Injection was administered immediately after randomization, 100 ml per dose, intravenously, twice...” NCT07528456 ↗ |
| Known as | Butylphthalide Soft Capsules, En Bi Pu (NBP) | “Butylphthalide Soft Capsules, En Bi Pu (NBP)” NCT00724724 ↗ |
| Known as | celery seed oil extract | “3-n-Butylphthalide (NBP), also known as celery seed oil extract, is a lipid-soluble compound isolated from celery seeds.” NCT07518810 ↗ |
| Known as | DL-3-n-butylphthalide | “Butylphthalide, as a well-known neuroprotective medication, is a family of compounds initially isolated from the seeds of Apium graveolens Linn, of which active ingredient is...” NCT03539445 ↗6“DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.” NCT02993367 ↗ “Dl-3-n-butylphthalide (NBP), isolated from the seeds of celery” NCT02594995 ↗ “DL-3-n-butylphthalide” NCT03906123 ↗ |
| Known as | NBP | “Our preliminary single-center study suggests that postoperative intravenous administration of dl-3-n-butylphthalide (NBP) may alleviate perioperative neurological deficits and...” NCT04205578 ↗10“Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising...” NCT07369999 ↗ “This study is designed to evaluate the safety and efficacy of butylphthalide (NBP) in the treatment of cerebral small vessel disease through a multicenter,...” NCT04078204 ↗ “Cerebrolysin and DL-3-n-butylphthalide (NBP) have each shown neuroprotective efficacy in preclinical models of acute ischemic stroke (AIS) and passed clinical trials as...” PMID 27168844 ↗ Mar 2016 “Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain.” NCT06353334 ↗ “3-n-Butylphthalide (NBP), also known as celery seed oil extract, is a lipid-soluble compound isolated from celery seeds.” NCT07518810 ↗ “DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.” NCT02993367 ↗ “Take 200 mg butylphthalide soft capsules (NBP) orally three times a day for 24 weeks” NCT06508671 ↗ “25mg butylphthalide(NBP) injection, and 100ml 0.9% saline” NCT03413202 ↗ |
| Modality | Small molecule | “DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.” NCT02993367 ↗ |
| Route | Oral | “20 mg/time per os three times a day.” NCT01405248 ↗ |